| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
AJ2-71 targets SLC15A4 (solute carrier family 15 member 4), a proton-coupled oligopeptide transporter involved in innate immune signaling. SLC15A4 mediates the transport of muramyl dipeptide (MDP) into cells, which activates the NOD2-RIPK2 pathway and promotes type I interferon production. By inhibiting SLC15A4, AJ2-71 blocks MDP transport and suppresses IFN-α production, thereby modulating inflammatory responses.
|
|---|---|
| ln Vitro |
In vitro, AJ2-71 inhibits SLC15A4-mediated MDP transport and suppresses IFN-α production. It demonstrates specificity for SLC15A4 inhibition, blocking the transporter's function in facilitating MDP uptake into cells. This inhibition disrupts the downstream NOD2-RIPK2 signaling cascade that leads to type I interferon production. AJ2-71 can be used for research of inflammation.
|
| ln Vivo |
In vivo, AJ2-71 may be utilized in inflammation research. By inhibiting SLC15A4-mediated MDP transport and suppressing IFN-α production, it has potential for studying chronic inflammatory diseases, including autoimmune and neurodegenerative conditions. The compound's specificity supports precise dissection of NLRP3 signaling mechanisms and evaluation of anti-inflammatory therapeutic strategies.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for AJ2-71 typically involves assessing its inhibition of SLC15A4-mediated transport. Cells expressing SLC15A4 are incubated with AJ2-71 at various concentrations in the presence of a labeled MDP substrate. Transport activity is measured by quantifying substrate uptake, and the IC50 for SLC15A4 inhibition is calculated from dose-response curves. IFN-α production can be measured in immune cells stimulated with MDP in the presence or absence of the compound.
|
| Cell Assay |
The in vitro cell-based assay for AJ2-71 involves culturing immune cells (such as macrophages or dendritic cells) that express SLC15A4 and respond to MDP stimulation. Cells are treated with AJ2-71 at various concentrations and then stimulated with MDP. IFN-α production is measured by ELISA, and NF-κB or other downstream signaling pathway activation is assessed by Western blot or reporter gene assays. Cell viability is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies for AJ2-71 would typically involve mouse models of inflammatory or autoimmune diseases. The compound would be administered orally or intraperitoneally at various doses. Inflammatory markers, cytokine levels, and disease severity would be assessed. Standard protocols for inflammation models would be employed. No specific in vivo data are available from publicly accessible sources.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of AJ2-71 have not been extensively characterized. As a small molecule with a molecular weight of 312.37 and a molecular formula of C20H16N4, it is expected to have moderate oral bioavailability. The compound can be formulated for in vivo administration using vehicles such as 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline. Detailed PK parameters are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of AJ2-71 has not been systematically evaluated. As a research compound targeting SLC15A4, its primary safety concerns would relate to effects on immune function and inflammatory responses. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| Additional Infomation |
AJ2-71 is a research compound and has not been approved for clinical use. It is a SLC15A4 inhibitor that suppresses IFN-α production and blocks SLC15A4-mediated MDP transport. AJ2-71 is valuable for studying chronic inflammatory diseases, including autoimmune and neurodegenerative conditions. Its specificity supports precise dissection of NLRP3 signaling mechanisms and evaluation of anti-inflammatory therapeutic strategies.
|
| Exact Mass |
312.14
|
|---|---|
| Elemental Analysis |
C, 76.90; H, 5.16; N, 17.94
|
| CAS # |
2700323-17-5
|
| Appearance |
White to off-white solid powder
|
| InChi Key |
VXDJUMYQUPVGOP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16N4/c1-2-6-15-13(5-1)9-10-16-14(11-21-19(15)16)12-22-20-23-17-7-3-4-8-18(17)24-20/h1-11,21H,12H2,(H2,22,23,24)
|
| Chemical Name |
N-((1H-benzo[g]indol-3-yl)methyl)-1H-benzo[d]imidazol-2-amine
|
| Synonyms |
AJ2-71; AJ271; AJ2 71
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
